论文部分内容阅读
澳大利亚R＆D公司Peplin Biotech近日宣布,早期临床试验显示:对传统疗法无反应的皮肤癌病人使用其外用抗癌新药,90％有应答。该公司将于2002年开始此药的Ⅲ期临床研究。
Australia’s R & D company Peplin Biotech recently announced that early clinical trials showed that 90% of patients with skin cancer who did not respond to traditional therapies responded with topical anticancer drugs. The company will begin phase III clinical trials of the drug in 2002.